Beck WT - Search Results

1

Antitopoisomerase drug action and resistance.

Nitiss JL, Beck WT. Nitiss JL, et al. Among authors: beck wt. Eur J Cancer. 1996 Jun;32A(6):958-66. doi: 10.1016/0959-8049(96)00056-1. Eur J Cancer. 1996. PMID: 8763336 Review. No abstract available.

2

Multidrug resistance and its circumvention.

Beck WT. Beck WT. Eur J Cancer. 1990 Apr;26(4):513-5. doi: 10.1016/0277-5379(90)90028-r. Eur J Cancer. 1990. PMID: 1972629 Review. No abstract available.

3

Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.

Kusumoto H, Rodgers QE, Boege F, Raimondi SC, Beck WT. Kusumoto H, et al. Among authors: beck wt. Cancer Res. 1996 Jun 1;56(11):2573-83. Cancer Res. 1996. PMID: 8653700

4

Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance.

Beck WT. Beck WT. J Natl Cancer Inst. 1989 Nov 15;81(22):1683-5. doi: 10.1093/jnci/81.22.1683. J Natl Cancer Inst. 1989. PMID: 2553990 No abstract available.

5

Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.

Chen M, Beck WT. Chen M, et al. Among authors: beck wt. Cancer Res. 1993 Dec 15;53(24):5946-53. Cancer Res. 1993. PMID: 8261408

6

Drug resistance associated with altered DNA topoisomerase II.

Beck WT, Danks MK, Wolverton JS, Kim R, Chen M. Beck WT, et al. Adv Enzyme Regul. 1993;33:113-27. doi: 10.1016/0065-2571(93)90012-3. Adv Enzyme Regul. 1993. PMID: 8395133 Review. No abstract available.

7

Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.

Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Weinstein R. Beck WT, et al. Cancer Res. 1996 Jul 1;56(13):3010-20. Cancer Res. 1996. PMID: 8674056 Review.

8

Altered DNA topoisomerase II in multidrug resistance.

Beck WT, Danks MK, Wolverton JS, Granzen B, Chen M, Schmidt CA, Bugg BY, Friche E, Suttle DP. Beck WT, et al. Cytotechnology. 1993;11(2):115-9. doi: 10.1007/BF00749000. Cytotechnology. 1993. PMID: 7764055 Review.

9

Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.

Kim R, Beck WT. Kim R, et al. Among authors: beck wt. Cancer Res. 1994 Sep 15;54(18):4958-66. Cancer Res. 1994. PMID: 8069863

10

Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells.

Beck WT, Kim R, Chen M. Beck WT, et al. Cancer Chemother Pharmacol. 1994;34 Suppl:S14-8. doi: 10.1007/BF00684858. Cancer Chemother Pharmacol. 1994. PMID: 8070022 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

134 results

Search Page